A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich society for chemotherapy (PEG) multicenter trial II

Infection

Volumn 34, Issue 3, 2006, Pages 118-126

  Schiel, X ^a   Link, H ^b   Maschmeyer, G ^c   Glass B ^d   Cornely, O A ^e   Buchheidt, D ^f   Wilhelm, M ^g   Silling, G ^h   Helmerking, M ⁱ   Hiddemann, W ^a   Ostermann, H ^a   Hentrich, M ^a,j  

^a UNIVERSITY OF MUNICH   (Germany)

^b Westpfalz Klinikum GmbH   (Germany)

^c KLINIKUM ERNST VON BERGMANN   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g KLINIKUM NÜRNBERG   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ ESBIC Study Center   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; ITRACONAZOLE; LEVOFLOXACIN; NETILMICIN; OFLOXACIN; PIPERACILLIN; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAVUCONAZOLE; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; CANCER PATIENT; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC SYSTEM TUMOR; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; LEUKEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES;

EID: 33745569393     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-006-5113-9     Document Type: Article

References (33)

1. Cometta A, Zinner S, De Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP: Piperacillin tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445-452.
2. Hughes WT, Armstrong D, Bodey CP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS: 1997 guidelines for the use of antimicobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551-573.
3. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332.
4. Behre G, Link H ,Maschmeyer G, Meyer P, Paaz U, Wilhelm M, Hiddemann W: Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of neutropenic patients. Ann Hematol 1998; 76: 73-80.
5. Böhme A, Shah PM, Stille W, Hölzer D: Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3: 324-330.
6. Cometta A, Calandra T, Gaya H, Zinner H, De Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken J, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP, and the International Antimicrobial Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto Infection Program: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
7. Feld R, DePauw B, Berman S, Keating A, Ho W: Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18: 3690-3698.
8. Paul M, Soares-Weiser K, Leibovici L: β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systemic review and meta-analysis. BMJ 2003; 326: 1-9.
9. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
10. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S: Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microb Infect Dis 1992; 11: 99-109.
11. Bennett JE, Powers J, Walsh T, Viscoli C, de Pauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, Verweij P: Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36(suppl 3): S117-S122.
12. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
13. EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-672.
14. Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, Adam D, for the Study Group of the Paul Ehrlich Society for Chemotherapy: Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 1994; 69: 231-243.
15. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BES: A randomized comparison of liposomal versus converntional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
16. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771.
17. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotercicin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155-1163.
18. Boogaerts M, Winston DJ, Bow EJ, Garber C, Reboli AC, Schwarer AP, Novitzky N, Böhme A, Chwetzoff E, De Beule K, and the Itraconazole Neutropenia Study Group: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-422.
19. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Lee J, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group: Voriconzole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
20. Walsh TJ, Teppler H, Donovitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely O, Bourque MR, Lupinacci RJ, Sable CA, de Pauw BE: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
21. Malik IA, Moid I, Aziz Z, Khan S, Suleman M: A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105: 479-483.
22. Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, Fanchi R, Menichetti F, Caselli D, Giacchino M, Congiu M: Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomized clinical trial. Eur J Cancer 1996; 32A: 814-820.
23. Winston DJ, Hathorn JW, Schuster MG, Schiller GI, Territo MC: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108: 282-289.
24. Wingard JR: Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39(suppl 1): S38-S43.
25. Hiddemann W, Essink ME, Fegeler W, Zuhlsdorf M, Sauerland C, Büchner T: Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia. Cancer 1991; 68: 9-14.
26. Francis P, Walsh TJ: Evolving role of flucytosine in immuncompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003-1018.
27. Klastersky J: Antifungal therapy in patients with fever and neutropenia - more rational and less empirical? N Engl J Med 2004; 351: 1445-1447.
28. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, on behalf of the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
29. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP, for the Intercontinental Antimicrobial Study Group: Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med 1994; 120: 834-844.
30. Rolston KVI: The Infectious Diseases of America 2002 guidelines for the use of antimicrobial agents in cancer and neutropenia: salient features and comments. Clin Infect Dis 2004; 39(suppl 1): 544-548.
31. Link H, Böhme A, Cornely OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW: Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Hematol 2003; 82(suppl2): S105-S117.
32. Erjavec Z, de Vries-Hospers HC, Laseur M, Halie RM, Daenen S: A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45: 843-849.
33. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C, for the International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382-389.